Can a New Combined Approach Revolutionize Liver Cancer Treatment?

Liver cancer, particularly hepatocellular carcinoma, remains one of the leading causes of cancer-related deaths worldwide. Current treatments such as surgery or local chemotherapy often show limitations in the face of recurrence and tumor resistance. A recent breakthrough suggests that an innovative combination could change the game.

Researchers have developed a strategy combining a technique called irreversible electroporation with NK cell-based immunotherapy. Irreversible electroporation uses electrical pulses to destroy cancer cells while preserving healthy tissue. This process also triggers a local immune response by releasing signals that attract immune system cells to the tumor.

NK cells, key players in natural immunity, are genetically modified here to specifically target a protein often present on the surface of liver cancer cells. This dual action not only directly eliminates part of the tumor but also makes the remaining cancer cells more vulnerable to NK cell attacks. Indeed, electroporation increases the production of molecules that promote NK cell infiltration into the tumor and stimulate their anticancer activity.

The results are promising: in animal models, this combined approach has shown a significant reduction in tumor size without major side effects. It works by altering the tumor’s immune environment, shifting it from a suppressive state to one that supports the immune response. The modified NK cells, once in place, recognize and destroy cancer cells more effectively.

This method opens a new therapeutic avenue for patients with advanced liver cancer. It could also be applied to other solid tumors where the tumor microenvironment limits the effectiveness of conventional immunotherapies. Its main advantage lies in its ability to act locally on the tumor while stimulating a broader and more durable immune response. Preclinical trials confirm its potential to improve survival and reduce the risk of recurrence, without systemic toxicity. This advancement could soon lead to new clinical protocols for patients with limited treatment options.

Legal Attributions

Study Citation

DOI: https://doi.org/10.1038/s41392-026-02627-2

Title: Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma

Journal: Signal Transduction and Targeted Therapy

Publisher: Springer Science and Business Media LLC

Authors: Joo Dong Park; Ha Eun Shin; Hye Jung Jang; Seunghyo Ko; Yeon Su An; Jun Seob Lee; Sehoon Moon; Hyungseok Seo; Yewon Kim; Yohan Kim; Jun-Hyeok Han; Chun Gwon Park; Dong-Hyun Kim; Wooram Park